XENE Q3 2019 Earnings — Xenon Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

XENEXenon Pharmaceuticals Inc.

$5B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M

Gross Profit

-$6M-178.6% margin

Operating Income

-$9M-255.7% margin

Net Income

-$9M-253.5% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$612,000

Balance Sheet

Total Assets

$99M

Total Liabilities

$24M

Stockholders' Equity

$75M

Cash & Equivalents

$38M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$0	—
Gross Profit	-$6M	-$6M	-4.2%
Operating Income	-$9M	-$14M	+36.9%
Net Income	-$9M	-$14M	+38.3%